Yae Kanai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yae Kanai has a total of 397 co-authors. Here are the top co-authors by number of shared publications:
- Tatsuhiro Shibata
Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan
86 shared publications - Shigehisa Kitano
Division of Cancer Immunotherapy Development, Department of Advanced Medical Development, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
85 shared publications - Nobuyoshi Hiraoka
Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan
72 shared publications - Teruhiko Yoshida
Department of Genetic Medicine and Services, National Cancer Center Hospital, Tokyo, Japan
71 shared publications - Akiyoshi Hirayama
Institute for Advanced Biosciences, Keio University, Yamagata, Japan
70 shared publications - Atsushi Ochiai
Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Japan
70 shared publications
Latest Publications
- 13 August 2026
- Published by Wiley in Hepatology Research
Des‐Gamma‐Carboxy Prothrombin Is Associated With Tumor Aggressiveness and Recurrence in Resected Early‐Stage Hepatocellular Carcinoma: A Clinicopathological and Molecular Analysis
Aim: Alpha‐fetoprotein (AFP) and des‐gamma‐carboxy prothrombin (DCP) are widely used tumor markers for hepatocellular carcinoma (HCC); however, their relative prognostic significance in early‐stage disease remains unclear. This study aimed to compare the prognostic impact of AFP and DCP in resected HCC and to explore their underlying molecular characteristics. Methods: We retrospectively analyzed 482 patients who underwent curative resection for HCC. Patients were classified into four groups according to AFP and DCP levels: Negative, AFP‐only, DCP‐only, and Dual‐positive. Recurrence‐free survival (RFS) and prognostic factors were evaluated. In a subset of 204 patients, gene expression profiling was conducted to investigate molecular differences. Results: Among BCLC stage 0/A patients ( n = 406), RFS was stratified according to tumor marker status. The DCP‐only group showed significantly worse RFS than the AFP‐only group (5‐year RFS: 39.5% vs. 52.7%, p = 0.026) and was characterized by larger tumor size (median, 39 vs. 18 mm, p < 0.001) and more frequent portal venous invasion (29% vs. 14%, p = 0.052). Multivariable analysis identified elevated DCP as an independent prognostic factor (hazard ratio 1.48, p = 0.004). In contrast, among stage B/C patients ( n = 76), survival outcomes were uniformly poor and not stratified by tumor marker. Gene expression analysis revealed the upregulation of SFN and downregulation of DCN in DCP‐elevated tumors, suggesting extracellular matrix destabilization that may contribute to tumor aggressiveness. Conclusions: Elevated DCP reflects aggressive tumor biology and identifies patients at high risk of recurrence after resection for BCLC stage 0/A HCC. These findings support the clinical utility of DCP for risk stratification and postoperative surveillance for early‐stage HCC.
- 13 August 2026
- Published by Wiley in Hepatology Research
Des‐Gamma‐Carboxy Prothrombin Is Associated With Tumor Aggressiveness and Recurrence in Resected Early‐Stage Hepatocellular Carcinoma: A Clinicopathological and Molecular Analysis
Aim: Alpha‐fetoprotein (AFP) and des‐gamma‐carboxy prothrombin (DCP) are widely used tumor markers for hepatocellular carcinoma (HCC); however, their relative prognostic significance in early‐stage disease remains unclear. This study aimed to compare the prognostic impact of AFP and DCP in resected HCC and to explore their underlying molecular characteristics. Methods: We retrospectively analyzed 482 patients who underwent curative resection for HCC. Patients were classified into four groups according to AFP and DCP levels: Negative, AFP‐only, DCP‐only, and Dual‐positive. Recurrence‐free survival (RFS) and prognostic factors were evaluated. In a subset of 204 patients, gene expression profiling was conducted to investigate molecular differences. Results: Among BCLC stage 0/A patients ( n = 406), RFS was stratified according to tumor marker status. The DCP‐only group showed significantly worse RFS than the AFP‐only group (5‐year RFS: 39.5% vs. 52.7%, p = 0.026) and was characterized by larger tumor size (median, 39 vs. 18 mm, p < 0.001) and more frequent portal venous invasion (29% vs. 14%, p = 0.052). Multivariable analysis identified elevated DCP as an independent prognostic factor (hazard ratio 1.48, p = 0.004). In contrast, among stage B/C patients ( n = 76), survival outcomes were uniformly poor and not stratified by tumor marker. Gene expression analysis revealed the upregulation of SFN and downregulation of DCN in DCP‐elevated tumors, suggesting extracellular matrix destabilization that may contribute to tumor aggressiveness. Conclusions: Elevated DCP reflects aggressive tumor biology and identifies patients at high risk of recurrence after resection for BCLC stage 0/A HCC. These findings support the clinical utility of DCP for risk stratification and postoperative surveillance for early‐stage HCC.
- Open Access
- 22 December 2025
- Published by Wiley in Pathology International
- Vol. 76 (1)
Prognostically Significant Glycan Profiles of Clear Cell Renal Cell Carcinoma Identified by Integrated Glycome–Methylome Analysis
The aim of this study was to clarify the clinicopathological significance of the glycan profile of clear cell renal cell carcinoma (ccRCC). Comprehensive glycomic analysis and methylome analysis were performed using 50 paired nontumorous renal tissue (N) and tumorous tissue (T) specimens from patients with ccRCC. In comparison to N samples, T samples showed higher signal intensities for lectins recognizing high‐mannose glycans and lower intensity for fucose and sialic acid, indicating that N‐type glycans remain “immature” in ccRCCs. Hierarchical clustering using the signal intensities of lectins recognizing high‐mannose glycans, fucose, and sialic acid divided T samples into Cluster A ( n = 32) and Cluster B ( n = 18). In Cluster B, the incidence of tumor‐related death was higher ( p = 0.017) and overall survival was lower ( p = 0.019). Moreover, asialo‐type glycans and N ‐acetyllactosamine residues, which are recognized by lectins DSA, ECA, and PHA‐E, had an impact on both recurrence‐free and overall survival. The expression of glycogenes, such as MGAT1 , ST6GAL1, and TUSC3 , may be epigenetically regulated. These results suggest that the glycan profile may be at least partly attributable to epigenetic regulation of glycogenes, and that comprehensive glycan profiling could provide clinically useful information for patients with ccRCC.
- 22 December 2025
- Published by Wiley in Pathology International
- Vol. 76 (1)
Open AccessPrognostically Significant Glycan Profiles of Clear Cell Renal Cell Carcinoma Identified by Integrated Glycome–Methylome Analysis
The aim of this study was to clarify the clinicopathological significance of the glycan profile of clear cell renal cell carcinoma (ccRCC). Comprehensive glycomic analysis and methylome analysis were performed using 50 paired nontumorous renal tissue (N) and tumorous tissue (T) specimens from patients with ccRCC. In comparison to N samples, T samples showed higher signal intensities for lectins recognizing high‐mannose glycans and lower intensity for fucose and sialic acid, indicating that N‐type glycans remain “immature” in ccRCCs. Hierarchical clustering using the signal intensities of lectins recognizing high‐mannose glycans, fucose, and sialic acid divided T samples into Cluster A ( n = 32) and Cluster B ( n = 18). In Cluster B, the incidence of tumor‐related death was higher ( p = 0.017) and overall survival was lower ( p = 0.019). Moreover, asialo‐type glycans and N ‐acetyllactosamine residues, which are recognized by lectins DSA, ECA, and PHA‐E, had an impact on both recurrence‐free and overall survival. The expression of glycogenes, such as MGAT1 , ST6GAL1, and TUSC3 , may be epigenetically regulated. These results suggest that the glycan profile may be at least partly attributable to epigenetic regulation of glycogenes, and that comprehensive glycan profiling could provide clinically useful information for patients with ccRCC.
- Open Access
- 5 December 2025
- Published by Elsevier in Human Pathology
- Vol. 167, 106001
Genome-wide DNA methylation profiling of pleomorphic carcinoma of the lung
- 5 December 2025
- Published by Elsevier in Human Pathology
- Vol. 167, 106001
Open AccessGenome-wide DNA methylation profiling of pleomorphic carcinoma of the lung
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary materials from Single-Cell Analysis Reveals a CD4+ T-cell Cluster That Correlates with PD-1 Blockade Efficacy
Legends of Supplementary Figures and Tables, and Supplementary Methods.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary materials from Single-Cell Analysis Reveals a CD4+ T-cell Cluster That Correlates with PD-1 Blockade Efficacy
Legends of Supplementary Figures and Tables, and Supplementary Methods.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1, S3 and S8 from Single-Cell Analysis Reveals a CD4+ T-cell Cluster That Correlates with PD-1 Blockade Efficacy
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1, S3 and S8 from Single-Cell Analysis Reveals a CD4+ T-cell Cluster That Correlates with PD-1 Blockade Efficacy
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2, S4, S5, S6 and S7 from Single-Cell Analysis Reveals a CD4+ T-cell Cluster That Correlates with PD-1 Blockade Efficacy
Supplementary Table 2, 4, 5, 6, 7.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2, S4, S5, S6 and S7 from Single-Cell Analysis Reveals a CD4+ T-cell Cluster That Correlates with PD-1 Blockade Efficacy
Supplementary Table 2, 4, 5, 6, 7.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Single-Cell Analysis Reveals a CD4+ T-cell Cluster That Correlates with PD-1 Blockade Efficacy
CD4+ T-cell immunity helps clonal proliferation, migration, and cancer cell killing activity of CD8+ T cells and is essential in antitumor immune responses. To identify CD4+ T-cell clusters responsible for antitumor immunity, we simultaneously analyzed the naïve-effector state, Th polarization, and T-cell receptor clonotype based on single-cell RNA-sequencing data. Unsupervised clustering analysis uncovered the presence of a new CD4+ T-cell metacluster in the CD62Llow CD4+ T-cell subpopulation, which contained multicellular clonotypes associated with efficacy of programmed death-ligand 1 (PD-1) blockade therapy. The CD4+ T-cell metacluster consisted of CXCR3+CCR4−CCR6+ and CXCR3−CCR4−CCR6+ cells and was characterized by high expression of IL7 receptor and TCF7. The frequency of these cells in the peripheral blood significantly correlated with progression-free survival and overall survival of patients with lung cancer after PD-1 blockade therapy. In addition, the CD4+ metacluster in the peripheral blood correlated with CD4+ T-cell infiltration in the tumor microenvironment, whereas peripheral Th1 correlated with local CD8+ T-cell infiltration. Together, these findings suggest that CD62Llow CCR4−CCR6+ CD4+ T cells form a novel metacluster with predictive potential of the immune status and sensitivity to PD-1 blockade, which may pave the way for personalized antitumor immunotherapy strategies for patients.Significance:The identification of a new CD4+ T-cell metacluster that corresponds with immune status could guide effective tumor treatment by predicting response to immunotherapy using peripheral blood samples from patients.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Single-Cell Analysis Reveals a CD4+ T-cell Cluster That Correlates with PD-1 Blockade Efficacy
CD4+ T-cell immunity helps clonal proliferation, migration, and cancer cell killing activity of CD8+ T cells and is essential in antitumor immune responses. To identify CD4+ T-cell clusters responsible for antitumor immunity, we simultaneously analyzed the naïve-effector state, Th polarization, and T-cell receptor clonotype based on single-cell RNA-sequencing data. Unsupervised clustering analysis uncovered the presence of a new CD4+ T-cell metacluster in the CD62Llow CD4+ T-cell subpopulation, which contained multicellular clonotypes associated with efficacy of programmed death-ligand 1 (PD-1) blockade therapy. The CD4+ T-cell metacluster consisted of CXCR3+CCR4−CCR6+ and CXCR3−CCR4−CCR6+ cells and was characterized by high expression of IL7 receptor and TCF7. The frequency of these cells in the peripheral blood significantly correlated with progression-free survival and overall survival of patients with lung cancer after PD-1 blockade therapy. In addition, the CD4+ metacluster in the peripheral blood correlated with CD4+ T-cell infiltration in the tumor microenvironment, whereas peripheral Th1 correlated with local CD8+ T-cell infiltration. Together, these findings suggest that CD62Llow CCR4−CCR6+ CD4+ T cells form a novel metacluster with predictive potential of the immune status and sensitivity to PD-1 blockade, which may pave the way for personalized antitumor immunotherapy strategies for patients.Significance:The identification of a new CD4+ T-cell metacluster that corresponds with immune status could guide effective tumor treatment by predicting response to immunotherapy using peripheral blood samples from patients.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer
Supplementary Figure S3. Method to generate macrophages and the phenotype of the macrophages.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer
Supplementary Figure S3. Method to generate macrophages and the phenotype of the macrophages.